VRCA Verrica Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1660334 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY370.2%
TTM net income YoY76.6%
TTM EPS YoY88.6%
Revenue 3-yr CAGR57.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-34.2%
Net margin-50.3%
FCF margin—
EBITDA margin-33.9%
Returns
ROE-240.4%
ROA-35.3%
ROIC (approx.)—
Asset turnover0.70x
Leverage & solvency
Liabilities / assets47.5%
Debt / equity0.00x
Current ratio2.59x
Interest coverage-1.57x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $35.58M | $7.57M |
| Cost of revenue | — | $2.60M |
| Gross profit | — | $4.97M |
| R&D expense | $8.86M | $11.84M |
| SG&A expense | $35.22M | $58.82M |
| Operating income | -$12.19M | -$65.92M |
| Interest expense | $7.74M | $9.41M |
| Income tax | $0 | $0 |
| Net income | -$17.89M | -$76.58M |
| EBITDA | -$12.05M | -$65.58M |
| EPS (basic) | -1.68 | -14.78 |
| EPS (diluted) | -1.68 | -14.78 |
| Weighted avg. shares (diluted) | 10.65M | 5.18M |
| Balance sheet | ||
| Cash & equivalents | $30.15M | $46.33M |
| Receivables | $5.26M | $48,000 |
| Inventory | $2.24M | $2.46M |
| Current assets | $42.54M | $51.18M |
| PP&E, net | $209,000 | $589,000 |
| Total assets | $47.13M | $54.13M |
| Current liabilities | $16.44M | $29.01M |
| Short-term debt | $0 | $12.94M |
| Long-term debt | $0 | $30.98M |
| Total debt | $0 | $43.92M |
| Total liabilities | $22.39M | $63.99M |
| Shareholders' equity | $24.74M | -$9.86M |
| Net debt | -$30.15M | -$2.41M |
| Shares outstanding | 17.18M | 9.18M |
| Cash flow statement | ||
| Operating cash flow | -$17.63M | -$60.93M |
| Capital expenditure | $0 | $27,000 |
| Free cash flow | -$17.63M | -$60.95M |
| Investing cash flow | $0 | -$19,000 |
| Financing cash flow | $1.45M | $37.73M |
| Depreciation & amortization | $133,000 | $342,000 |
| Stock-based compensation | $3.32M | $7.16M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.